SpringWorks Therapeutics Trading Volume Surges to $393 Million, Ranks 221st Amid Potential Merck KGaA Takeover

On April 24, 2025, SpringWorks Therapeutics Inc. (SWTX) saw a significant surge in trading volume, reaching $393 million, marking a 399.16% increase from the previous day. This placed the company at the 221st position in terms of trading volume for the day. The stock price of SpringWorks rose by 9.03%, marking the third consecutive day of gains, with a total increase of 21.24% over the past three days.

SpringWorks Therapeutics Inc. experienced a notable rise in its stock price on Thursday afternoon, driven by reports of a potential takeover by Germany’s Merck KGaA. The Wall Street Journal reported that the two companies are nearing a $47 per share takeover deal, with a definitive agreement potentially being announced as early as Monday. This potential acquisition has been in the works since at least February, when Merck KGaA confirmed advanced talks to acquire the cancer and rare diseases drugmaker.

Earlier in the week, an analyst highlighted that a recently concluded CHMP meeting on SpringWorks’ Ogsiveo could help de-risk the potential deal. EU approval of Ogsiveo is seen as a key catalyst for a takeover. Ogsiveo is the first FDA-approved therapy for patients with desmoid tumors who require systemic treatment, having received FDA approval in November 2023.